Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
October 21, 2022
RegMed Investors’ (RMi) closing bell: no ladders needed; the tide went out and today came back in
October 21, 2022
RegMed Investors’ (RMi) pre-open: climbing the ladder of share pricing
October 20, 2022
RegMed Investors’ (RMi) closing bell: The upside didn’t last long after Wednesday’s extreme downside from an upside open
October 20, 2022
RegMed Investors’ (RMi) pre-open: weakness
October 19, 2022
RegMed Investors’ (RMi) closing bell: wipe-out
October 19, 2022
RegMed Investors’ (RMi) pre-open: I’d be letting the upsiders run and then fast walk share pricing profits
October 18, 2022
RegMed Investors’ (RMi) closing bell: a choppy sector session
October 18, 2022
RegMed Investors’ (RMi) pre-open: how many signals are needed to forecast the sector’s move
October 17, 2022
RegMed Investors’ (RMi) pre-open: earnings are the elephant in the room
October 14, 2022
RegMed Investors’ (RMi) closing bell: risk and sentiment have broken through cell and gene therapy equities
35 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.